Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
WZ4003: Redefining NUAK1/2 Inhibition in Cancer and Tauopath
2026-05-19
WZ4003, a highly selective NUAK1/2 inhibitor, is reshaping translational research by linking mechanistic kinase targeting to tangible advances in cancer biology and neurodegenerative disease models. This article bridges evidence from landmark studies to practical guidance, highlighting both the opportunities and boundaries for experimentalists leveraging this tool.
-
Icatibant for Severe Viral Infections: Evidence from Hantavi
2026-05-18
This article reviews the application of icatibant, a bradykinin B2 receptor antagonist, in the management of severe viral infections, particularly Puumala hantavirus and COVID-19. Drawing on clinical case reports and a randomized trial, it examines how modulating the kinin-kallikrein system may impact vascular permeability and patient outcomes, with implications for translational research in antiviral therapy.
-
Influenza Hemagglutinin (HA) Peptide: Precision in Epitope T
2026-05-18
Harness the Influenza Hemagglutinin (HA) Peptide for high-fidelity protein detection, purification, and interaction studies. Discover applied protocols, troubleshooting insights, and workflow optimizations that set this HA tag peptide apart in translational research.
-
Adefovir (GS-0393): Precision Workflows in HBV Antiviral Res
2026-05-17
Adefovir (GS-0393) stands out as both a gold-standard HBV DNA polymerase inhibitor and a highly specific renal OAT1 probe, offering experimental precision where off-target effects can compromise data quality. This article delivers actionable workflow enhancements, troubleshooting strategies, and comparative insights for hepatitis B virus research, leveraging primary literature and APExBIO's rigorously validated product.
-
Rotigotine Hydrochloride: Translational Strategy for Dopamin
2026-05-16
This thought-leadership article provides an in-depth, mechanistically driven guide for translational researchers leveraging Rotigotine hydrochloride—a potent dopamine D2/D3 receptor agonist—in neurodegenerative disease models. Integrating cutting-edge evidence on receptor biology, nanoparticle nose-to-brain delivery, and workflow optimization, this piece offers strategic insights extending beyond conventional summaries. APExBIO's Rotigotine hydrochloride is spotlighted as a gold-standard research compound, with practical parameters, validated protocols, and a forward-looking outlook for the next era of Parkinson's disease research.
-
Oligo (dT) 25 Beads: Practical Guidance for mRNA Purificatio
2026-05-15
Oligo (dT) 25 Beads provide a robust solution for isolating intact eukaryotic mRNA via magnetic bead-based workflows, minimizing rRNA and genomic DNA contamination. These beads are ideal for applications requiring high-purity mRNA, such as first-strand cDNA synthesis and RT-PCR, but are not intended for prokaryotic RNA or non-polyadenylated transcripts.
-
Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina
2026-05-15
This study reveals that gramine, a natural indole alkaloid, inhibits triple-negative breast cancer (TNBC) by inducing ferroptosis through CUL3-mediated ubiquitination of MTDH. The findings identify a novel regulatory axis with therapeutic potential for TNBC and inform future mechanistic and proteomic investigations.
-
Translating Ferroptosis Inhibition: Liproxstatin-1 for Next-
2026-05-14
This thought-leadership article provides translational researchers with a strategic, mechanism-rich exploration of Liproxstatin-1 as a ferroptosis inhibitor. Integrating insights from recent cuproptosis research, comparative cell death pathways, and evolving organ injury models, it delivers actionable guidance for advanced ferroptosis research. The discussion is underpinned by primary data, nuanced protocol recommendations, and cross-referencing with seminal literature and APExBIO’s robust product documentation.
-
β-Amanitin in Transcriptional Studies: Workflows & Innovatio
2026-05-14
Harness β-Amanitin's unique inhibition of RNA polymerase II to dissect gene expression mechanisms and improve mRNA synthesis inhibition assays. This guide distills protocol enhancements, troubleshooting insights, and the translational value of computationally guided detection methods, all grounded in cutting-edge research and APExBIO’s high-purity offering.
-
DMH-1 (SKU B3686): Precision ALK2 Inhibition for Organoid an
2026-05-13
This scenario-driven article guides biomedical researchers and lab technicians through the practical deployment of DMH-1 (SKU B3686), a selective ALK2 inhibitor, to address reproducibility obstacles in cell viability, proliferation, and cytotoxicity assays. Drawing on recent peer-reviewed advances and validated workflows, it demonstrates how DMH-1 delivers reliable BMP signaling inhibition for organoid and non-small cell lung cancer (NSCLC) models, with actionable guidance on protocol optimization and vendor selection.
-
MHY1485: Precision mTOR Activation for Next-Gen Autophagy As
2026-05-13
Explore how MHY1485, a potent mTOR activator, enables unprecedented control in autophagy assays and ovarian follicle development research. This article reveals new, actionable insights grounded in recent mechanistic studies and offers protocol guidance distinct from prior reviews.
-
Targeting the ERα DBD-LBD Interface with Mitoxantrone: A Nov
2026-05-12
This study uncovers a previously unexploited vulnerability in estrogen receptor alpha (ERα), demonstrating that mitoxantrone binds the DBD-LBD interface to drive rapid receptor degradation via proteasomal pathways. The work establishes a new paradigm for DNA topoisomerase II inhibitors in overcoming resistance in breast cancer, with significant implications for research on receptor dynamics and therapeutic intervention.
-
D-Luciferin Sodium Salt: Optimizing Bioluminescence in Oncol
2026-05-12
D-Luciferin sodium salt is the gold-standard firefly luciferase substrate, enabling ultra-sensitive, ATP-dependent bioluminescence assays for cell viability and metabolism monitoring. Discover how cutting-edge workflows, including mRNA-LNP programming of CAR macrophages, are revolutionizing bioluminescence imaging in oncology research with this robust reagent.
-
Adefovir (GS-0393): Optimizing HBV Antiviral Research Workfl
2026-05-11
Adefovir (GS-0393) stands apart as a water-soluble, high-purity nucleotide analog for hepatitis B virus (HBV) research, offering robust DNA polymerase inhibition and precise OAT1 transporter probing. This guide details practical protocols, advanced use-cases, and troubleshooting strategies to maximize the translational reliability of your antiviral studies.
-
CX-5461: RNA Polymerase I Inhibitor for Advanced Cancer Rese
2026-05-11
CX-5461 from APExBIO stands out as a robust, orally bioavailable RNA polymerase I inhibitor, enabling precise targeting of ribosome biogenesis in cancer cells. With deep literature support and protocol-driven reliability, it empowers researchers to interrogate autophagy, senescence, and chemoresistance mechanisms in solid tumors with unprecedented clarity.